The DOI matches its Crossref record; 282 of the 282 references it cites were found in a registry or an index.
Emerging targets in cancer immunotherapy
Open accessAbstract
The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor immune responses. These agents led to unprecedented results in patients with previously incurable metastatic disease and may become first-line therapies for some advanced cancers. However, these agents are efficacious in only a minority of patients. Newer strategies are becoming available that target additional immunomodulatory mechanisms to activate patients' own anti-tumor immune responses. Herein, we present a succinct summary of emerging immune targets with reported pre-clinical efficacy that have progressed to active investigation in clinical trials. These emerging targets include co-inhibitory and co-stimulatory markers of the innate and adaptive immune system. In this review, we discuss: 1) T lymphocyte markers: Lymphocyte Activation Gene 3 [LAG-3], T-cell Immunoglobulin- and Mucin-domain-containing molecule 3 [TIM-3], V-domain containing Ig Suppressor of T cell Activation [VISTA], T cell ImmunoGlobulin and ITIM domain [TIGIT], B7-H3, Inducible T-cell Co-stimulator [ICOS/ICOS-L], CD27/CD70, and Glucocorticoid-Induced TNF Receptor [GITR]; 2) macrophage markers: CD47/Signal-Regulatory Protein alpha [SIRPα] and Indoleamine-2,3-Dioxygenase [IDO]; and 3) natural killer cell markers: CD94/NKG2A and the Killer Immunoglobulin-like receptor [KIR] family. Finally, we briefly highlight combination strategies and potential biomarkers of response and resistance to these cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–282 of 282
Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
Shapiro, M., Herishanu, Y., Katz, B., Dezorella, N., Sun, C., Kay, S., Polliack, A., Avivi, I. M., Wiestner, A. U., & Perry, C. (2017) · Haematologica · doi:10.3324/haematol.2016.148965 · Cited by 98
Rocca, Y. S., Roberti, M. P., Juliá, E. P., Pampena, M. B., Bruno, L., Rivero, S., Huertas, E., Sánchez Loria, F., Pairola, A., Caignard, A., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00413 · Cited by 97
Loss of heterozygosity and tumor suppressor activity ofBin1 in prostate carcinoma
Ge, K., Minhas, F., DuHadaway, J. B., Mao, N.-C., Wilson, D. M., Buccafusca, R., Sakamuro, D., Nelson, P. S., Malkowicz, S. B., Tomaszewski, J., et al. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000415)86:2<155::aid-ijc2>3.0.co;2-m · Cited by 97
Xu, L., Yang, L., Yao, D., Wu, X., Li, J., Liu, X., Deng, L., Huang, C., Wang, Y., Li, D., et al. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.01.001 · Cited by 97
Le, K.-S., Thibult, M., Just-Landi, S., Pastor, S., Gondois‐Rey, F., Granjeaud, S., Broussais, F., Bouabdallah, R., Colisson, R., Caux, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0589 · Cited by 96
NK Cell Phenotypic Modulation in Lung Cancer Environment
Jin, S., Deng, Y.-N., Hao, J.-W., Li, Y., Liu, B., Yu, Y., Shi, F.-D., & Zhou, Q.-H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109976 · Cited by 94
Peperzak, V., Veraar, E. A. M., Keller, A. M., Xiao, Y., & Borst, J. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000159 · Cited by 93
Loenen, W. A. M., de Vries, E., Gravestein, L. A., Hintzen, R. Q., van Lier, R. A. W., & Borst, J. G. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220224 · Cited by 92
Van, V. Q., Lesage, S., Bouguermouh, S., Gautier, P., Rubio, M., Lévesque, M., Nguyen, S., Galibert, L., & Sarfati, M. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601415 · Cited by 92
Ingebrigtsen, V. A., Boye, K., Nesland, J. M., Nesbakken, A., Flatmark, K., & Fodstad, Ø. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-602 · Cited by 90
Owonikoko, T. K., Hussain, A., Stadler, W. M., Smith, D. C., Kluger, H. M., Molina, A. M., Gulati, P., Shah, A., Ahlers, C. M., Cardarelli, P. M., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2909-2 · Cited by 88
Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer
Meng, Q., Liu, Z., Rangelova, E. B., Poiret, T., Ambati, A., Rane, L., Xie, S., Verbeke, C. S., Dodoo, E., Chiaro, M. D., et al. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000111 · Cited by 85
CD47 Ligation Selectively Inhibits the Development of Human Naive T Cells into Th1 Effectors
Avice, M.-N., Rubio, M., Sergerie, M., Delespesse, G., & Sarfati, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4624 · Cited by 84
Xiao, Y., Peperzak, V., Keller, A. M., & Borst, J. G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1071 · Cited by 83
Late Signals from CD27 Prevent Fas-Dependent Apoptosis of Primary CD8+ T Cells
Dolfi, D. V., Boesteanu, A. C., Petrovas, C., Xia, D., Butz, E. A., & Katsikis, P. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2912 · Cited by 83
Schildknecht, A., Miescher, I., Yagita∥, H., & van den Broek, M. F. (2007) · European Journal of Immunology · doi:10.1002/eji.200636824 · Cited by 82
Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma
Danielsen, J. M. R., Knudsen, L. M., Dahl, I. M. S., Lodahl, M., & Rasmussen, T. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06729.x · Cited by 81
ERAP1 Regulates Natural Killer Cell Function by Controlling the Engagement of Inhibitory Receptors
Cifaldi, L., Romania, P., Falco, M., Lorenzi, S., Meazza, R., Petrini, S., Andreani, M., Pende, D., Locatelli, F., & Fruci, D. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1643 · Cited by 78
Veenstra, R. G., Flynn, R. P., Kreymborg, K. G., McDonald-Hyman, C. S., Saha, A., Taylor, P. A., Osborn, M. J., Panoskaltsis‐Mortari, A., Schmitt-Graeff, A. H., Lieberknecht, E., et al. (2015) · Blood · doi:10.1182/blood-2014-09-603357 · Cited by 77
Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., Maleski, J. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o7 · Cited by 77
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies
Pittari, G., Filippini, P., Gentilcore, G., Grivel, J., & Rutella, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00230 · Cited by 74
Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells
Gillard, M., Caer, C., Cagnard, N., Crozet, L., Perez, M., Fridman, W. H., Sautès‐Fridman, C., & Cremer, I. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00019 · Cited by 73
Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity
Casati, C., Camisaschi, C., Rini, F., Arienti, F., Rivoltini, L., Triebel, F., Parmiani, G., & Castelli, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2728 · Cited by 72
Levy, E. M., Sycz, G., Arriaga, J. M., Barrio, M. M., von Euw, E. M., Morales, S. B., Gonzalez, M. S., Mordoh, J., & Bianchini, M. (2009) · Innate Immunity · doi:10.1177/1753425908101404 · Cited by 69
Pedroza‐González, A., Zhou, G., Singh, S. P., Boor, P. P. C., Pan, Q., Grünhagen, D. J., de Jonge, J., Tran, T. K., Verhoef, C. K., IJzermans, J. N. M., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1051297 · Cited by 69
An Orthotopic Colon Cancer Model for Studying the B7-H3 Antitumor Effect In Vivo
Lupu, C., Eisenbach, C., Kuefner, M. A., Schmidt, J., Lupu, A., Stremmel, W., & Encke, J. (2006) · Journal of Gastrointestinal Surgery · doi:10.1007/bf03239969 · Cited by 68
Keller, A. M., Xiao, Y., Peperzak, V., Naik, S. H., & Borst, J. G. (2009) · Blood · doi:10.1182/blood-2008-03-148007 · Cited by 68
Bin1 Ablation Increases Susceptibility to Cancer during Aging, Particularly Lung Cancer
Chang, M. Y., Boulden, J., Katz, J. B., Wang, L., Meyer, T. J., Soler, A. P., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1100 · Cited by 67
Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control
Tu, M. M., Mahmoud, A. B., & Makrigiannis, A. P. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00166 · Cited by 66
Carr, J. M., Carrasco, M. J., Thaventhiran, J. E. D., Bambrough, P. J., Kraman, M., Edwards, A. D., Al‐Shamkhani, A., & Fearon, D. T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609706104 · Cited by 65
TIMs: central regulators of immune responses
Hafler, D. A., & Kuchroo, V. K. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20082429 · Cited by 65
Differing Phenotypes between Intraepithelial and Stromal Lymphocytes in Early-Stage Tongue Cancer
Katou, F., Ohtani, H., Watanabe, Y., Nakayama, T., Yoshie, O., & Hashimoto, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2637 · Cited by 63
B7-H3 expression in breast cancer and upregulation of VEGF through gene silence
Sun, J., Guo, Y., Li, X., Zhang, Y., Gu, L., Wu, P., Bai, G., & Xiao, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s63424 · Cited by 62
Gravestein, L. A., Blom, B., Nolten, L. A., de Vries, E., Horst, G., OSSENDORP, F. A., Borst, J. G., & Loenen, W. A. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230427 · Cited by 61
Tajiri, T., Liu, X., Thompson, P. M., Tanaka, S., Suita, S., Zhao, H., Maris, J. M., Prendergast, G. C., & Hogarty, M. D. (2003) · PubMed · Cited by 61
Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia
Hu, Y., Lv, X., Wu, Y., Xu, J., Wang, L., Chen, W., Zhang, W., Li, J., Zhang, S., & Qiu, H. (2014) · Hematology · doi:10.1179/1607845414y.0000000186 · Cited by 60
Arsenic trioxide synergizes with B7H3‐mediated immunotherapy to eradicate hepatocellular carcinomas
Luo, L., Qiao, H., Meng, F., Dong, X., Zhou, B., Jiang, H., Kanwar, J. R., Krissansen, G. W., & Sun, X. (2005) · International Journal of Cancer · doi:10.1002/ijc.21557 · Cited by 58
Chang, W., Li, C., Huang, S., Chang, D., Chou, L., & Sheu, B. (2010) · Cancer · doi:10.1002/cncr.25371 · Cited by 56
Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma
Chang, W., Li, C.-H., Chu, L.-H., Huang, P.-S., Sheu, B., & Huang, S. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000578 · Cited by 56
Alomar, S. Y., Middleton, D., Marshall, E., Porter, D., Xinarianos, G., Raji, O. Y., Field, J. K., & Christmas, S. E. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.06.019 · Cited by 54
Cariani, E., Pilli, M., Barili, V., Porro, E., Biasini, E., Olivani, A., Valle, R. D., Trenti, T., Ferrari, C. I., & Missale, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1154249 · Cited by 54
Aida, K., Miyakawa, R., Suzuki, K. A. O., Narumi, K., Udagawa, T., Yamamoto, Y., Chikaraishi, T., Yoshida, T., & Aoki, K. (2013) · Cancer Science · doi:10.1111/cas.12332 · Cited by 53
Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes
Olsson, M., Nilsson, A. K., & Oldenborg, P. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.002 · Cited by 52
Leyland, R., Watkins, A., Mulgrew, K. A., Holoweckyj, N., Bamber, L., Tigue, N. J., Offer, E., Andrews, J. L., Li, Y., Mullins, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2000 · Cited by 52
Lee, H., Kim, J. H., Yang, S. Y., Kong, J., Oh, M., Jeong, D. H., Chung, J., Bae, K. B., Shin, J. Y., Hong, K. H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0800-4 · Cited by 50
Richter, G. H. S., Hayden-Ledbetter, M. S., Irgang, M., Ledbetter, J. A., Westermann, J., Körner, I. J., Daemen, K., Clark, E. A., Aicher, A., & Pezzutto, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108509200 · Cited by 50
B7-H3 regulates the development of experimental allergic conjunctivitis in mice
Fukushima, A., Sumi, T., Fukuda, K., Kumagai, N., Nishida, T., Yamazaki, T., Akiba, H., Okumura, K., Yagita∥, H., & Ueno, H. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.07.011 · Cited by 49
Fossati‐Jimack, L., da Silveira, S. A., Moll, T., Kina, T., Kuypers, F. A., Oldenborg, P., Reininger, L., & Izui, S. (2002) · Journal of Autoimmunity · doi:10.1006/jaut.2001.0563 · Cited by 49
Bin1 Ablation in Mammary Gland Delays Tissue Remodeling and Drives Cancer Progression
Chang, M. Y., Boulden, J., Sutanto‐Ward, E., DuHadaway, J. B., Soler, A. P., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2742 · Cited by 47
Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation
Gigoux, M., Lovato, A., Leconte, J., Leung, J., Sonenberg, N., & Suh, W. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.01.008 · Cited by 46
Expression of immune checkpoints in T cells of esophageal cancer patients
Xie, J.-H., Wang, J., Cheng, S., Zheng, L., Ji, F., Yang, L., Zhang, Y., & Ji, H. (2016) · Oncotarget · doi:10.18632/oncotarget.11611 · Cited by 46
Chen, X., Quinn, E. M., Ni, H., Wang, J., Blankson, S., Redmond, H. P., Wang, J. H., & Feng, X. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103715 · Cited by 44
Sakanishi, T., & Yagita∥, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.092 · Cited by 44
The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue
Nelson, M. H., Kundimi, S., Bowers, J. S., Rogers, C. E., Huff, L. W., Schwartz, K. M., Thyagarajan, K., Little, E. C., Mehrotra, S., Cole, D. J., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401082 · Cited by 43
The T cell activation molecule H4 and the CD28-like molecule ICOS are identical
Buonfiglio, D., Bragardo, M., Redoglia, V., Vaschetto, R., Bottarel, F., Bonissoni, S., Bensi, T., Mezzatesta, C., Janeway, C. A., & Dianzani, U. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(2000012)30:12<3463::aid-immu3463>3.0.co;2-5 · Cited by 43
Ly49 Family Receptors Are Required for Cancer Immunosurveillance Mediated by Natural Killer Cells
Tu, M. M., Mahmoud, A. B., Wight, A. E., Mottashed, A., Bélanger, S., Rahim, M. M. A., Abou-Samra, E., & Makrigiannis, A. P. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3021 · Cited by 43
Tezuka, K., Tsuji, T., Hirano, D., Tamatani, T., Sakamaki, K., Kobayashi, Y., & Kamada, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3466 · Cited by 42
Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group
Jobim, M. R. S. L., Jobim, M., Salim, P. H., Portela, P., Jobim, L. F. J., Leistner‐Segal, S., Bittelbrunn, A. C. D. C., Menke, C. H., Biazús, J. V., Roesler, R., et al. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.06.021 · Cited by 40
Tigue, N. J., Bamber, L., Andrews, J. L., Ireland, S., Hair, J. R., Carter, E. P., Sridharan, S., Jovanović, J., Rees, D. G., Springall, J. S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1280645 · Cited by 40
Linedale, R., Schmidt, C., King, B., Ganko, A. G., Simpson, F., Panizza, B. J., & Leggatt, G. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175755 · Cited by 40
Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation
Oliveira, P., Carvalho, J., Rocha, S., Azevedo, M., Reis, I., Camilo, V., Sousa, B., Valente, S., Paredes, J., Almeida, R., et al. (2016) · Scientific Reports · doi:10.1038/srep34860 · Cited by 37
Ueno, T., Yeung, M. Y., McGrath, M. M., Yang, S., Zaman, N., Snawder, B., Padera, R. F., Magee, C. N., Gorbatov, R., Hashiguchi, M., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242501 · Cited by 36
Zhou, P., Qiu, J., L’Italien, L., Gu, D., Hodges, D., Chao, C., & Schebye, X. M. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6ba9 · Cited by 35
B7-H3 Contributes to the Development of Pathogenic Th2 Cells in a Murine Model of Asthma
Nagashima, O., Harada, N., Usui, Y., Yamazaki, T., Yagita∥, H., Okumura, K., Takahashi, K., & Akiba, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4062 · Cited by 33
SIRPα Controls the Activity of the Phagocyte NADPH Oxidase by Restricting the Expression of gp91phox
van Beek, E. M., Zárate, J. Á., van Bruggen, R., Schornagel, K., Tool, A. T. J., Matozaki, T., Kraal, G., Roos, D., & van den Berg, T. K. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.027 · Cited by 32
Martínez‐Canales, S., Cifuentes, F. T., de Rodas, M. L., Serrano‐Oviedo, L., Galán‐Moya, E. M., Amir, E., Pandiella, A., Győrffy, B., & Ocaña, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175128 · Cited by 32
Wiśniewski, A., Jankowska, R., Passowicz−Muszyńska, E., Wiśniewska, E., Majorczyk, E., Nowak, I., Frydecka, I., & Kuśnierczyk, P. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.07.323 · Cited by 30
Krausz, L. T., Fischer‐Fodor, E., Major, Z. Z., & Fetică, B. (2012) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201202500108 · Cited by 30
Beksaç, K., Beksaç, M., Dalva, K., Karaağaoğlu, E., & Tirnaksiz, M. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132526 · Cited by 28
Valentin, M. D., Navarro, A. G., Rahman, M. A., Kumar, S., Retière, C., Ulvestad, E., Kristensen, V. N., Lund‐Johansen, M., Lie, B. A., Enger, P. Ø., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1162 · Cited by 28
Li, C., Kuo, W., Chang, W., Huang, S., Chang, K., & Sheu, B. (2011) · Immunologic Research · doi:10.1007/s12026-011-8242-x · Cited by 27
Zhao, L., Liu, X., Guo, R., & Wang, P. (2017) · Tumor Biology · doi:10.1177/1010428317698352 · Cited by 27
Yu, N., Fu, S., Xu, Z., Liu, Y., Hao, J., Zhang, A., & Wang, B. (2015) · International Journal of Cancer · doi:10.1002/ijc.29713 · Cited by 25
GITR agonist enhances vaccination responses in lung cancer
Zhu, L. X., Davoodi, M., Srivastava, M. K., Kachroo, P., Lee, J. M., John, M. A. S., Harris‐White, M. E., Huang, M., Strieter, R. M., Dubinett, S. M., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.992237 · Cited by 21
Pace, E., Sano, C. D., Ferraro, M., Tipa, A., Olivieri, D., Spatafora, M., Santagata, R., Bellia, V., & Gjomarkaj, M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.001 · Cited by 16
Brunn, N. D., Mauze, S., Gu, D., Wiswell, D., Ueda, R., Hodges, D., Beebe, A. M., Zhang, S., & Escandón, E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229864 · Cited by 16
Immune Rejection of Mouse Tumors Expressing Mutated Self
Duan, F., Lin, Y., Liu, C., Engelhorn, M. E., Cohen, A. D., Curran, M. A., Sakaguchi, S., Merghoub, T., Terzulli, S. L., Wolchok, J. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2779 · Cited by 15
Analysis of KIR gene frequencies and HLA class I genotypes in prostate cancer and control group
Portela, P., Jobim, L. F. J., Salim, P. H., Koff, W. J., Wilson, T. J., Jobim, M. R. S. L., Schwartsmann, G., Roesler, R., & Jobim, M. (2012) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2012.01115.x · Cited by 13
Giebel, S., Boratyn-Nowicka, A., Karabon, L., Jedynak, A., Pamuła‐Piłat, J., Tęcza, K., Kula, D., Kowal, M., Frydecka, I., & Grzybowska, E. A. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.04.002 · Cited by 9
Wang, W., Erbe, A. K., Gallenberger, M., Kim, K., Carmichael, L. L., Hess, D., Mendonça, E. A., Song, Y., Hank, J. A., Cheng, S., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1904-8 · Cited by 6
Abstract 1201: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer
Loo, D. T., Scribner, J. A., Son, T., Hooley, J., Hotaling, T. E., Chiechi, M., Li, P., Costa, A. D., Chen, Y., Easton, A. N., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-1201 · Cited by 4
Abstract 573: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody
Michaelson, J. S., Harvey, C. J., Elpek, K. G., Duong, E., Wallace, M., Shu, C. J., Sathyanarayanan, S., Mabry, R., Shallberg, L. A., Zi, T., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-573 · Cited by 1
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Gangoso, E., Southgate, B., Bradley, L., Rus, S., Galvez-Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 359
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Metadata
- Authors
- Burugu, S., Dancsok, A. R., & Nielsen, T. O.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 52
- Issue
- Pt 2
- Pages
- 39-52
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2761081415
- Cited by
- 314
- References
- 282
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.